In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s shares closed yesterday at $11.60.
Werber covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Argenx Se, and Celldex. According to TipRanks, Werber has an average return of 23.4% and a 61.90% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $14.83 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Roivant Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $37.14 million and a net profit of $5.1 billion. In comparison, last year the company earned a revenue of $17.05 million and had a GAAP net loss of $352.01 million
Based on the recent corporate insider activity of 130 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roivant Sciences (ROIV) Company Description:
Montes Archimedes Acquisition Corp is a blank check company.
Read More on ROIV:
- Roivant Sciences management to meet with Cantor Fitzgerald
- 5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024
- Wolfe starts Roivant at Outperform, notes robust balance sheet
- Roivant Sciences initiated with an Outperform at Wolfe Research
- Roivant Sciences price target lowered to $17 from $18 at H.C. Wainwright
